Novo Nordisk heeds KBP Biosciences’ CLARION call

Novo Nordisk’s metabolic juggernaut semaglutide is known to work in chronic kidney disease – but the group appears to want a back-up plan.   

Kidneys

Despite stopping semaglutide’s FLOW study in patients with type 2 diabetes and chronic kidney disease (CKD) early for efficacy on October 10, Novo Nordisk A/S has decided to buy another, differently acting, product for a similar use (Also see "The FLOW Of Novo Nordisk's Semaglutide Success Rolls Into Kidney Disease" - Scrip, 11 October, 2023.). It has bought the non-steroidal mineralocorticoid receptor antagonist (MRA) ocedurenone from KBP BioSciences Co Ltd for up to $1.3bn.

Key Takeaways

  • The Danish group will pay up to $1.6bn for KBP Biosciences’ ocedurenone

Novo is making much of its new acquisition’s potential in uncontrolled hypertension, but ocedurenone’s ongoing Phase III trial is actually...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip